General information regarding CHIP are available at.. These new grants are part of a broader effort to find and enroll uninsured kids who are eligible for Medicaid or CHIP but not enrolled. As needed in CHIPRA, grants will become awarded by the Centers for Medicare & Medicaid Services to candidates whose outreach, enrollment and retention initiatives will focus on geographic areas with high rates of eligible but uninsured American Indian and Alaska Native children, who reside in isolated areas and so are uninsured at higher-than-average rates often. Related StoriesReducing hospital readmissions through Transitional Treatment: an interview with Rani KhetarpalICD-10 Clinical Modification: an interview with Dr.The IND for Staccato loxapine was filed with the FDA in August 2005. AZ-004 has shipped a predictable and consistent basic safety and efficacy profile in dealing with sufferers with agitation, stated James V. Cassella, PhD, Senior Vice President, Development and Research in Alexza. We believe that AZ-004, if approved, gets the potential to improve the treatment practices for acute agitation, as the just product able to meet both patients’ desire for quickly and comfortably attaining control, and the clinicians’ goal of rapidly and reliably calming an agitated patient. The info we have seen from the Staccato loxapine trials are compelling, said Michael Lesem, MD, Executive Medical Director, Claghorn-Lesem Study Clinic, Houston, TX.